GPBAR1 and metabolic dysfunction-associated steatohepatitis: BAR502, is a dual FXR and GPBAR1 agonist32–34, that is currently advanced to clinical stage, that was shown effective in reducing steatosis and fibrosis in rodents model of NAFLD and NASH.